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A B S T R A C T  
Background: In 1998 a clinical guideline for the targeted,
accurate and early detection and treatment of HFE-related
hereditary haemochromatosis (HH), which comprises a
test for the causative HFE-gene mutations, was introduced
in our outpatient department.
Methods: The impact of this guideline was evaluated
retrospectively. Data were acquired from medical records
of patients with discharge diagnosis codes suggestive of
HH (n=878 patients), obtained from a period before
(n=422) and after guideline introduction (n=456). 
Results: Combined measurements of serum transferrin
saturation and serum ferritin rose from 12.2% (n=53) to
29.5% (n=138, p<0.001), leaving 70% of the patients eligible
for HH not tested for iron parameters. The HFE-gene
mutation detection test was correctly used in 11 (40.7%)
of 27 tested patients and improperly interpreted in six
(22.2%) of these 27 patients. Five new HH patients were
diagnosed before and 13 after introduction. Seven of these
13 patients appeared to be incorrectly diagnosed, due to
misinterpretation of laboratory results. Diagnostic costs
of case detection for each accurately diagnosed patient
were € 2380 before and € 2600 after introduction of the
guideline.
Conclusion: Evaluation of the introduction of a practical
guideline for targeted HH detection reveals a low com-
pliance with the guideline, resulting in both a small per-
centage of patients tested for HH and overdiagnosis of
HH. Therefore, the introduction of the guideline should
be combined with a more appropriate implementation
strategy which includes education on its most critical
points, i.e. the indication and interpretation of the iron
parameters and the HFE genotype.
K E Y W O R D S
Genetic testing, guideline adherence, haemochromatosis,
practice guideline, serum iron measurements
I N T R O D U C T I O N
The medical and scientific interest in HFE-related heredi-
tary haemochromatosis (HH), iron overload disease,
quickly expanded after the discovery of the causative
C282Y and H63D mutations in the haemochromatosis
(HFE) gene in 1996.1 The C282Y mutation is now the
most common autosomal recessive mutation in people of
northern European descent, with an estimated prevalence
of the genetic susceptibility for HH by homozygous
C282Y mutation of one in 200 to 250 persons.2,3
Symptoms that can be attributed to iron overload are
fatigue, arthralgia and cardiac rhythm disorders.4-6
Furthermore, diabetes mellitus, elevated liver enzymes,
liver cirrhosis, hepatocellular carcinoma and cardiac failure
can be considered as signs of HH,5,7,8 the last three being
the most common cause of death in untreated HH
patients.6,7
The first step in the diagnosis of HH consists of the
recognition that these symptoms and signs in combination
with persistent elevated serum transferrin saturations and
elevated serum ferritin concentrations may be attributed
to HH, especially when these laboratory values remain
unexplained.4,5,9,10 The diagnosis of HH is confirmed by
the presence of homozygosity for the C282Y mutation, by
compound heterozygosity for the C282Y and H63D
mutation in the HFE gene and by iron overload shown in
a liver biopsy, on exclusion of secondary causes of iron
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tissue accumulation such as ineffective erythropoiesis,
haemolysis, concomitant liver pathology and recurrent
blood transfusions.2,5,10 Treatment consists of extraction
of the excessive amount of iron from the body by phle-
botomy.4,5,11 When these phlebotomies are initiated before
the development of irreversible symptoms and damage,
HH patients have a normal life expectancy.11,12 Therefore,
it is crucial that patients with HH are detected early in the
course of the disease by measurement of their (elevated)
serum iron parameters. However, these parameters are
often not evaluated, as HH patients frequently present at
the age of 50 to 60 years with nonspecific symptoms, which
are often ascribed to age-related and common disorders.5,13
This nonspecific presentation of the disorder reduces
recognition of the disease and leads to high medical
consumption and associated medical and nonmedical
costs.14,15 To enhance the awareness among physicians of
HH in patients with these nonspecific symptoms and to
improve the quality and effectiveness of the diagnostic
pathway of HH, including the new HFE-mutation analysis,
a guideline for case detection and treatment of HFE-related
HH was developed in our university hospital in 1998 by a
multidisciplinary haemochromatosis study group. 
In the present study we aimed to evaluate retrospectively
i) physicians’ compliance with the diagnostic procedures,
ii) the number of detected HH patients, iii) the correctness
of the HH diagnoses, and iv) costs per detected patient,
during a two-year period before and after introduction of
the clinical guideline. 
M E T H O D S  
The multidisciplinary guideline was introduced in 1998
and contained recommendations to screen for HH when
a patient presented with signs or symptoms as described
in figure 1. The guideline was developed in our university
hospital by a multidisciplinary haemochromatosis study
group. This group consisted of physicians from the
departments of general internal medicine, haematology,
rheumatology, clinical genetics, gastroenterology and
clinical chemistry. International evidence-based studies and
expert opinion were translated into a guideline suitable for
the local situation.8,11,16-20 The guideline was introduced
and explained during sessions held in the outpatient
department of internal medicine of our university medical
hospital. After its introduction, the guideline was available
on the intranet of our hospital server. 
According to the guideline, HH was diagnosed in symp-
tomatic patients when the serum transferrin saturation
was above 50% on at least two different occasions (one of
which after overnight fasting), in combination with a
serum ferritin concentration at least twice the upper limit
of the normal value of 280 g/l. For the diagnosis of HH
Jacobs, et al. Guideline for HH detection.
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it was recommended to exclude other factors that are
known to influence the iron parameters, such as blood
transfusions, iron supplementation, haemolytic anaemia,
(alcoholic) hepatitis, non-HH-related liver disease and
acute or chronic infections. Thus, a correctly diagnosed
HH patient was defined as a patient with an elevation of
both serum iron parameters in the absence of concomitant
factors that influence iron parameters.
After detection of the biochemical iron overload, the
guideline recommended testing for the C282Y and H63D
mutation in the HFE gene to determine whether the
patient had an HFE-related form of HH (figure 1). Genetic
testing was also recommended for first-degree relatives of
a symptomatic HFE-related HH proband. Liver biopsy
was advised when a persisted elevation of both iron
parameters was combined with a serum alanine amino-
transferase (ALAT) or aspartate aminotransferase (ASAT)
concentration more than twice the normal value, to either
exclude concomitant liver pathology or to obtain a prog-
nosis for the condition of the iron overloaded liver. When
either HFE genotype (C282Y homozygosity and
C282Y/H63D compound heterozygosity) or liver biopsy
confirmed the diagnosis of HH, family screening and
treatment was recommended (figure 1). The latter consist-
ed of phlebotomy therapy in two phases. The first phase
of weekly phlebotomies was meant to withdraw iron from
the overloaded tissues, the second phase, of two to eight
phlebotomies a year, to maintain a low body iron level.
For first-degree relatives who appeared to be C282Y
homozygous or C282Y/H63D compound heterozygous
and had not yet developed iron overload, a phlebotomy
schedule consisting of two blood donations a year, similar
to that used for regular blood donors, was recommended
(figure 1). 
We retrospectively compared the diagnostic procedures
for patients with features suggestive of HH who visited
the outpatient department of internal medicine between a
period before (January 1995 to December 1996) and after
(May 2000 to April 2002) introduction of the guideline.
The choice of the latter period allowed sufficient time for
uptake of the novel procedures from the 1998 guideline,
whereas the first period was chosen before the discovery
of the HFE-gene mutation.1
Patients
Patients were selected for evaluation by using discharge
diagnosis codes (classification system ICD-9-CM-codes).21
Some patients received more than one diagnosis code.
The discharge codes included were ‘unexplained chronic
fatigue for more than six months’, ‘elevated liver enzymes or
liver cirrhosis without explanation’, ‘unexplained arthralgia’,
‘diabetes mellitus’, ‘hereditary haemochromatosis’ or ‘iron
metabolism disorders’ and ‘porphyria cutanea tarda’.
Inclusion of diabetes mellitus patients was restricted to
patients with concomitant elevation of liver enzymes
(more than twice the upper limit of the reference value).
Excluded were diabetes mellitus type 1 patients under the
age of 35, patients suffering from chronic viral hepatitis,
chronic alcohol abuse at the time of the study, cholestatic
pathology and HH patients diagnosed with iron overload
HH elsewhere. By means of an inventory form the following
data were extracted from the medical records: serum
transferrin saturation, serum ferritin concentration,
HFE-mutation analysis, liver biopsy, HH diagnosis and
the presence of co-factors that might result in falsely
elevated iron parameters (such as blood transfusions,
iron supplementation, haemolytic anaemia, (alcoholic)
hepatitis, acute or chronic infections, hepatic injury and
end-stage liver disease). 
Compliance and statistics
Compliance of the physicians with the guideline was
calculated by (number of guideline items followed)/(items
followed + items not followed) x 100%. These items
consisted of serum transferrin saturation, serum ferritin
concentration, HFE-gene testing and liver biopsy. For the
period before guideline introduction the same items,
except the HFE-gene testing, were scored. Differences in
diagnosis codes, gender, age and compliance scored before
and after guideline introduction were tested for significance
using a 2 test.
Costs
The impact of the guideline introduction on resource
utilisation was assessed, taking into account direct 
medical costs only. The costs for diagnosing HH were
approximated from laboratory costs (serum transferrin
saturation, serum ferritin and HFE-mutation detection)
and the costs for ultrasound-guided liver biopsy, with one-
day hospital stay. For unit cost prices, national rates were
used as proxies of actual resource utilisation, except for
hospitalisation, for which a standard cost price was
used.22 Volumes of tests used were derived from chart
review. Costs per case of correctly diagnosed HH patients
were calculated and expressed in Euros.
R E S U L T S
Patient selection and characteristics
During the two observation periods, a total of 9096
individual patients visited the outpatient department of
internal medicine, providing us with 902 discharge diag-
nosis codes consistent with the possible presence of HH
representing 878 patients, 422 patients from the period
before and 456 patients from the period after guideline
introduction (table 1). In addition, 16 patients could not be
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Serum transferrin saturation ≥50% and
serum ferritin concentration ≥280 g/l
on at least two occasions
Hereditary
haemochromatosis1
Hereditary haemochromatosis suspected in the 
presence of
• Unexplained chronic fatique for more than 6 months
• Elevation of liver enzymes without known cause
• Arthralgia of unknown origin existing longer than 
 6 months
• Polyarthrosis before the age of 50
• Cardiac rhythm disorders without diagnosis
• Unexplained heart failure
• Porphyria cutanea tarda
• Unexplained impotence and infertility
• Diabetes mellitus with elevated liver enzymes
• Unexplained iron storage in liver biopsy
• First-degree family members diagnosed with 
 HFE-related PH
Liver biopsy when ALAT
or ASAT are twice
the normal value2
Hereditary
haemochromatosis
(confirmed)
HFE-testing
C282Y and H63D
mutation3
Treatment with 
phlebotomies with- 
drawal and maintenance
phase4
Family screening
biochemical and genetic
in first degree
family members5
1Provided concomitant factors which influence the iron parameters,
such as blood transfusions, iron supplementation, haemolytic anaemia,
non-HH related liver disease and acute or chronic infection, could
be excluded. Whenever doubt with respect to liver pathology, liver
biopsy was recommended. 2To exclude concomitant liver pathology
or to obtain a prognosis for the condition of the iron overloaded
liver. 3For confirmation of the diagnosis HFE-related HH. C282Y
homozygosity and C282Y/H63D compound heterozygosity confirm
the diagnosis HFE-related HH. HFE testing was also advised when
the patient had first-degree relatives with known HFE-related HH.
4Two blood donations a year with control of the iron parameters once
every three years, was recommended for C282Y homozygous and
C282Y/H63D compound heterozygous first-degree family relatives,
of a HFE-related proband clinically expressing HH, who had not yet
developed iron overload. 5Genetic HH screening was recommended
only when the proband was diagnosed with HFE-related HH. PH =
primary haemochromatosis, ALAT = alanine aminotransferase;
ASAT = aspartate aminotransferase.
Figure 1 Flowchart guideline for targeted detection of hered-
itary haemochromatosis (HH) as introduced in 1998
included as their medical records were missing; four
from the period before and 12 from the period after
guideline introduction (table 1).
Of the patients, 352 (40%) were male; 177 (41.9%) in the
group before and 175 (38.4%) after guideline introduction
(table 2). Overall, 561 (63.8%) of the patients were 50 years
of age or older (table 2).
Diagnostic accuracy
Serum iron parameters
In the period before guideline introduction, serum trans-
ferrin saturation was measured in 29.7% (n=129) of all
diagnosis codes. After introduction of the guideline, this
percentage rose to 36.8% (n=172, p<0.05) (table 3). The
serum ferritin measurements were performed in 17.3%
(n=75) of the patients before and in 71.8% (n=336, p<0.001)
after introduction. This significant rise in serum ferritin
measurements was observed for patients from all diagnosis
codes, except for those with ‘liver cirrhosis of unknown
origin’. There was a pronounced rise in serum ferritin
measurements for the diagnosis codes of ‘chronic fatigue
of unknown origin’ (from 10.9% (n=32) before to 74.7%
(n=245, p<0.001) after), ‘diabetes mellitus with elevated
liver enzymes’ (from 18.0 % (n=11) before to 44.9%
Jacobs, et al. Guideline for HH detection.
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Table 2 Gender and age ( >50 years) of the patients included
Before implementation After implementation Total
n % n % n %
Gender
All 422 48.13 56 51.93 878 100.03
Male 177 41.91 175 38.42 352 40.03 ns4
Female 245 58.11 281 61.62 526 60.03 ns4
Age >50 years
All 268 63.51 293 64.12 561 63.83
Male 113 26.81 97 21.22 210 23.93 ns4
Female 155 36.71 196 42.92 351 39.93 ns4
1100% = total included patients in the group before implementation (n=422). 2100% = total included patients in the group after implementation
(n=456). 3100% = total included patients of the two periods together (n=878). 4Significance of difference between the periods before and after
implementation of the guideline. n = number of patients.
Table 1 Discharge diagnosis codes included in the study for both the periods before and after introduction of the
guideline
Diagnosis codes Number of diagnosis codes
Before introduction After introduction
n %1 n %1
Arthralgia, of unknown origin, >6 months 16 3.7 18 3.8 ns2
Chronic fatigue, of unknown origin, >6 months 294 67.7 328 70.1 ns2
Diabetes mellitus with elevated liver enzymes3 61 14.1 49 10.5 ns2
Haemochromatosis or disturbed iron metabolism 6 1.4 13 2.8 ns2
Liver enzyme elevation of unknown origin4 27 6.2 52 11.1 p<0.052
Liver cirrhosis of unknown origin 26 6.0 8 1.7 p<0.0012
Porphyria cutanea tarda 4 0.9 0 0.0 n.d.
Medical records not available5 4 0.9 12 2.6 ns2
Total number of included diagnosis codes 434 468
Total number of included patients6 422 456
1100% = total of diagnosis codes included in that period. 2Significance of difference in number of patients included between the periods before
and after implementation of the guideline. 3All patients diagnosed with diabetes mellitus type 2 or diabetes mellitus type 1 after the age of 35
years. Liver enzymes were elevated when they were more than twice the normal values. 4Cholestatic diseases, viral hepatitis and chronic alcohol
abuse at time of diagnosis were excluded. 5Diagnosis codes of patients’ medical records that were not available: before introduction three codes
‘diabetes of unknown origin’ and one code ‘chronic fatigue’, after introduction 12 codes ‘adult onset diabetes mellitus of unknown origin’. 6One
patient could have more than one diagnosis code. ns = non significant; n.d. = not determined.
(n=22, p<0.01) after) and ‘elevated liver enzymes of
unknown origin’ (from 29.6% (n=8) before to 73.1%
(n=38, p<0.01) after). The hallmark test for the diagnosis
of HH, i.e. the combination of serum transferrin saturation
and serum ferritin measurement, also increased with
guideline introduction from 12.2% (n=53) in the period
before to 29.5% (n=138, p<0.001) in the period after
guideline introduction. This rise in combined measure-
ment of serum transferrin saturation and serum ferritin
concentration was significant for all diagnosis codes,
except for the small groups of patients diagnosed with
‘arthralgia of unknown origin’ and ‘liver cirrhosis of
unknown origin’. For all the discharge codes the absolute
number of serum transferrin saturation measurements
was comparable with the absolute number of serum
ferritin measurements after guideline introduction. Only
the ‘chronic fatigue of unknown origin’ defined group
showed a striking difference between the two measure-
ments: 87 serum transferrin saturation measurements vs
245 serum ferritin measurements in the period after
guideline introduction.
HFE-mutation analysis 
HFE-gene mutation analyses were performed in 27
patients after protocol introduction (table 4). According to
the guideline, HFE testing was recommended for only 11
(40.7%) of these 27 patients (numbers 1-11); nine of them
had a combination of elevated serum transferrin saturation
and elevated serum ferritin concentration and two of
them were screened within the framework of family
screening. In six of these 11 patients the clinical diagnosis
HH could be confirmed on follow-up, since both iron
parameters remained elevated and no other explanation
to account for these elevated levels was found (table 4).
One of them had a non-HFE-related form of HH, confirmed
by the amount of iron withdrawn by phlebotomy to
obtain normal serum iron parameters (number 6). In
three of these 11 patients the HH diagnosis could not be
confirmed (numbers 7-9): one patient’s liver biopsy con-
tained no iron, one patient’s serum transferrin saturation
returned to normal levels when measured on a second
occasion and one patient had normal transferrin saturation
levels, which alternated with high transferrin saturation
levels upon blood transfusion. The physicians were correct
not to diagnose HH in these three patients. The two
patients who were HFE-gene tested in the context of family
screening (numbers 10 and 11) were falsely diagnosed as
iron overloaded and treated as HH patients. The guide-
line recommended follow-up of these patients and to
phlebotomise them only twice a year. The remaining 16
(of the 27) HFE-tested patients should not have been tested
following the guideline, since only one of the two serum
iron parameters was elevated. Moreover, five of these 16
patients (numbers 12-16) were incorrectly diagnosed with
HH by the physicians, for some of them most likely
based on their HFE-gene genotype only. 
Three patients were not tested for HFE-gene mutations
in the period after guideline introduction despite their
combination of elevated serum iron parameters. In two of
these three patients serum iron parameters appeared to
be temporarily influenced by blood transfusions. The
remaining patient underwent a liver biopsy to exclude
liver pathology. This liver biopsy revealed no iron.
Liver biopsy
Liver biopsies were taken for 60 diagnosis codes, repre-
senting 53 patients, 26 (49.1%) before and 27 (50.9%)
after guideline introduction. In 49 of these 53 patients,
the decision to perform a liver biopsy was based on a
suspicion of concomitant liver disease. In four of these
53 patients, liver biopsy was performed in the absence of
elevated liver enzymes or (probable) liver disease. Three
of these four patients underwent liver biopsy before
guideline introduction and the availability of the HFE-gene
test. All three patients had elevated serum transferrin
saturations (>50%) and serum ferritin levels (>280 g/l).
The presence of an increased amount of iron in their
liver biopsy (diagnosed by an independent pathologist)
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Table 3 Diagnostic test use for serum iron parameters before and after guideline introduction
Serum iron parameters Diagnosis codes
Before implementation After implementation
n % n %
Serum transferrin saturation 129 29.7 172 36.8 p<0.051
Serum ferritin concentration 75 17.3 336 71.8 p<0.0011
Combination of serum TS and serum ferritin concentration 53 12.2 138 29.5 p<0.0011
Diagnostic test use is expressed as the percentage of the total number of diagnosis codes included in that period. Data are obtained from the 
medical records. Both the serum transferrin saturation and the serum ferritin concentration were scored no more than once per diagnosis code.
1Significance of difference in increase in serum iron parameter(s) between the periods before and after implementation of the guideline. TS =
transferrin concentration.
confirmed the diagnosis HH. The remaining fourth
patient underwent his biopsy after guideline introduction
in the presence of an elevated serum transferrin saturation
and in the absence of an increased serum ferritin level.
The liver biopsy revealed no increased amount of iron
and HH was correctly excluded.
Number of detected patients
The introduction of the guideline led to an increase in
diagnoses of HH, from five patients (1.2%) before to 13
patients (2.9%) after introduction of the guideline (table 4).
This increase, however, was not statistically significant.
Phlebotomy treatment was started for all 18 patients. 
The physicians’ diagnoses of iron overload appeared to be
incorrect for seven of the 13 patients, as at least one of the
serum iron parameters was not elevated (patients 10-16,
table 4). Three of these patients were at risk of developing
iron overload based on their C282Y homozygosity, but
had not yet developed iron overload as their ferritin levels
were normal (patients 10-12). All three were females and
aged 41, 45 and 55 years, respectively. There was no over-
diagnosis of HH before guideline introduction.
In total, we found one case of a missed HH diagnosis
(patient 33, table 4). In this patient, included in the group
Jacobs, et al. Guideline for HH detection.
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Table 4 Characteristics of patients in whom HFE-gene analysis was performed or who were diagnosed with heredi-
tary haemochromatosis according to the physicians or the guideline
Serum iron parameters HFE gene mutations Liver biopsy HH diagnosis
PatientEvaluationTransferrin Ferritin C282Y H63D Physician3 Guideline3
period1 saturation ≥280 g/l2
≥50%2
1 After + + Heterozygous Heterozygous n.d. + +
2-5 After + + Homozygous Negative n.d. + +
6 After + + Negative Negative n.d. + +4
7 After + + Heterozygous Negative n.d. _ _5
8 After + + Negative Negative Micro nodular cirrhosis, _ _
Perls negative
9 After + + Negative Heterozygous n.d. _ _5
10-11 After + _ Homozygous Negative n.d. + _6
12 After + _ Homozygous Negative Perls negative + _
13 After _ + Heterozygous Negative n.d. + _
14 After _ _ Heterozygous Negative n.d. + _
15 After _ + Negative Homozygous n.d. + _
16 After _ + Negative Negative n.d. + _
17-18 After _ + Negative Heterozygous Steatosis, Perls negative _ _
19 After _ + Negative Negative Steatohepatitis, Perls negative _ _
20 After + _ Negative Heterozygous Perls negative _ _
21 After _ + Negative n.d. n.d. _ _
22-23 After _ + Negative Negative n.d. _ _
24 After _ _ Heterozygous Heterozygous n.d. _ _
25 After _ _ Negative Heterozygous n.d. _ _
26 After _ + Negative Negative n.d. _ _
27 After _ _ Negative Negative n.d. _ _
28-29 Before + + n.a n.a n.d. + +7
30 Before + + n.a n.a Perls positive, + +7
hepatocellular carcinoma
31 Before + + n.a n.a Perls positive + +7
32 Before + + n.a n.a Perls positive, cirrhosis + +7
33 Before n.a n.a n.a n.a Autopsy liver: _ + 
Perls positive, cirrhosis
Hereditary haemochromatosis (HH) diagnoses according to the physician: diagnoses of iron overload based on clinical grounds and treatment
started for HH. HH diagnoses according to the guideline: HH diagnoses that should have been given according to the guideline. 1Before = peri-
od before guideline implementation; after = period after guideline implementation. 2- = Transferrin saturation <50% or serum ferritin <280
g/l; + = transferrin saturation ≥50% or serum ferritin ≥280 g/l. 3- = No HH diagnosed; + HH diagnosed. 4Non-HFE related HH. 5Serum
transferrin saturation that normalised when measured on a second occasion. 6Patient was a first-degree relative of an HFE-gene-related HH
patient. 7HH diagnoses confirmed with either liver biopsy or number of phlebotomies. n.d. = not determined; n.a. = not available; Perls = Perls’
staining, Prussian blue reaction used to detect iron in a liver biopsy.
before guideline introduction, the diagnosis of HH was
only made postmortem, on autopsy. During life, the
diagnosis of liver cirrhosis of unknown origin had been
made. No iron parameters had been measured.
For nine patients with a combination of an elevated
serum transferrin saturation and serum ferritin, HH was
not diagnosed. Three of these patients were included in
the period before and six patients were included in the
period after guideline introduction. One patient from the
first period was diagnosed with porphyria cutanea tarda
and transferred to another hospital before further diagnosis
and treatment could take place. For all the remaining
eight patients the diagnosis of HH was correctly excluded
either based on clinical evidence (blood transfusions
recently given or spontaneous normalisation of iron
parameters), or by a liver biopsy containing no increased
amount of iron.
Costs
The total cost associated with the detection of new HH
patients before introduction of the guidelines amounted
to € 11,900. After the introduction, these costs rose to 
€ 15,600. When these costs were ascribed to patients
correctly diagnosed with iron overload proven HH, this
resulted in € 2380 per correctly diagnosed patient before
and € 2600 per correctly diagnosed patient after intro-
duction of the guideline.
D I S C U S S I O N
The introduction of the guideline for targeted HFE-related
HH detection in the outpatient department of general
internal medicine of our university hospital in 1998 led to
an increased number of patients with symptoms consistent
with HH, who were tested for serum iron parameters
(serum transferrin saturation and ferritin). The number
of HH diagnoses rose when compared with a period
before guideline introduction. This rise, however, was not
statistically significant. A shortcoming of the introduction
of the guideline was the increase in the number of
patients falsely diagnosed with HH. 
The increase in both serum transferrin saturation and
serum ferritin measurements in the period after intro-
duction of the guideline was likely to result from the guide-
line introduction. This increase might have been positively
influenced by more recently (after 1998) introduced
guidelines in the department of internal medicine, i.e. on
‘arthralgia’ and on ‘liver cirrhosis’, which incorporated
the recommendations of the HH guideline of 1998. It
should, however, be noted that despite these increased
numbers of iron parameters measured after guideline
introduction, still approximately 70% of the patients with
symptoms and signs consistent with HH were not tested
for these parameters.
There was a remarkable difference in the magnitude of
the raise in serum transferrin saturation and in serum
ferritin measurements in the diagnosis code group
‘chronic fatigue of unknown origin’ after guideline intro-
duction. This could be explained by the implementation
of a guideline on ‘chronic fatigue’ in the outpatient
department in 1999, which recommended only the
measurement of serum ferritin, not combined with
serum transferrin saturation, to detect HH among
patients with symptoms suggestive of chronic fatigue.
Guideline compliance was also evaluated by the use of
liver biopsies in the diagnosis of HH. According to the
guideline, liver biopsies should be used to exclude additional
liver pathology or to obtain a prognosis for the condition
of the iron overloaded liver. Before the discovery of the
HFE gene, liver biopsy was the gold standard for the con-
firmation of the diagnosis of hereditary iron overload.
The compliance for the use of liver biopsies after the
introduction of the guideline was good. Only one patient
underwent a liver biopsy without elevation of both serum
iron parameters or a possible liver disease. 
The current study did not provide solid information on
compliance with family screening for HH. However, the
few notations made on this subject in the medical files
suggested that physicians advised the proband to inform
his or her family of the necessity of clinical, biochemical
and/or genetic screening for HH. 
Medical costs due to diagnostic procedures for each
accurately diagnosed patient were similar before and after
guideline introduction. However, these costs do not
include costs due to incorrect diagnoses, i.e. patients in
whom HH was missed or patients who were incorrectly
diagnosed as having HH, nor do they include costs for
treatment.
Compliance with the therapeutic aspects of the guideline
was not thoroughly evaluated in the present study.
However, it appeared that three homozygous C282Y
patients of the 13 subjects diagnosed with HH were
phlebotomised despite the absence of iron overload. For
non-iron overloaded homozygous C282Y relatives of HH
patients as well as for C282Y/H63D compound heterozygous
relatives, the guideline recommended performing two
blood donations twice a year as prevention. However,
treatment of these non-iron overloaded patients is 
controversial and various treatment protocols have been
proposed. Shortly after the discovery of the HFE gene,
therapeutic protocols for these patients, such as the proto-
col described here, were based on the assumption of a
high penetrance of the HFE-gene mutation and advised:
i) performing phlebotomies several times a year to prevent
iron accumulation, in order to maintain the serum ferritin
level around 50 g/l5 and ii) twice yearly blood donation,
with control of the iron parameters once every three years
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(present guideline).23 Since evidence is accumulating that
the phenotypic penetrance of homozygosity for the
C282Y mutation is low, it is currently advised to only
start treatment when iron overload is proven and control
for clinical and biochemical manifestations of HH every
ten to twenty years.24
A drawback of the guideline introduction was the incorrect
diagnosis of iron overload for several patients after guide-
line introduction (n=7). This was mainly due to erroneous
use and interpretation of the HFE genotype (n=6). It
appeared that HFE testing was more often used than strictly
indicated and that once the HFE gene was genotyped, it
dominated the results of the serum iron parameters and
the liver biopsy. This dominant use and overestimation of
the value of the HFE genotype in the diagnostic process
of HH might be attributed to misinterpretation of the
huge amount of international literature since 1996 which
suggested the clinical relevance of the C282Y mutation
due to the high clinical penetrance.3,25-28 Only recently,
evidence has accumulated that this penetrance of the
homozygosity for the HFE-gene C282Y mutation might
be very low.9,29-32 But also, the fact that the diagnostic
strategy of the present guideline lacks solid scientific
evidence on its most crucial points (similar to the strat-
egies throughout literature)4,10,11,33,34 and is mainly based on
professional expertise, might have decreased compliance. 
While awaiting the calculation of the cost-effectivity of
both population and cascade screening, most HH
patients in the Netherlands are still detected by case
detection, i.e. early detection of patients with HH who
seek medical attention for symptoms suggestive of HH.
According to a recent report by Cadet et al. this strategy of
targeted HH detection has been proven to be cost-effective.35
Also the present study shows the potential cost-effectivity
of targeted case detection in comparison with population
screening as approximately one in 80 patients (1:84 (5 in
422) patients before, to 1:76 (6 in 457) patients after
guideline introduction) have biochemical proven iron
overload in comparison with one in 280 to one in 400
patients in the general population of northern European
origin.36,37 A disadvantage of this targeted approach,
however, is the potential diagnostic delay in the course of
the disease. 
There were some limitations inherent to the study. First
of all it was a retrospective study. This implicated that we
had to interpret the thoughts of the physicians on the
differential diagnosis of their patients’ symptoms by
looking at the diagnostic investigations performed on each
patient. For example, we cannot be sure that every serum
ferritin or serum transferrin saturation was performed in
the light of HH diagnostics. Moreover, elevated iron levels
might have been missed and with this also potential
patients with HH, with a risk for organ damage and early
death.2,26 It is not possible to give solid numbers for those
patients not recognised as having HH in the current study.
As 87.8% (n=381) of the diagnosis codes eligible for HH
before and 70.5% (n=330) of these diagnosis codes after
guideline introduction were not evaluated for serum iron
parameters, there could have been a fair number of missed
HH diagnoses. However, for all the patients who were
tested for both their serum iron parameters, we conclude
that no eligible HH patients were incorrectly judged as
being healthy. This also implicates that when HH was not
diagnosed, despite the elevation of both serum iron
parameters, this was done on correct clinical grounds,
taking into account concomitant treatment or diseases, as
the guideline recommended. The second limitation was
the lack of control group. Therefore, we cannot exclude
that the rise in diagnostic procedures is explained by the
increase in the number of physicians who adhered to a
more ‘defensive’ kind of medicine by adding test and/or
the general trend in time for an increased use of iron
parameters (i.e. ferritin) in the last decade.
We conclude that due to a relatively low compliance to the
guidelines: i) approximately 70% of the patients with
symptoms and signs consistent for HH were not tested
for serum iron parameters and consequently patients
with HH might have been missed and on the other hand
ii) indication and interpretation of the genetic and iron
parameters were misunderstood with as a result overdiag-
nosis of HH. The reasons why physicians do not follow
clinical practice guidelines have been described by several
groups.38-40 One of them, Cabana et al., clearly reviewed
and summarised the literature on this subject in 1999.
This resulted in the recognition of a variety of barriers
to guideline adherence, which include: i) knowledge
(awareness, familiarity), ii) attitude (agreement, self-efficacy,
outcome expectancy, ability to overcome the inertia of
previous practice) and iii) external barriers to performing
recommendations. We believe that in general these barriers
all attributed partly to the less optimal compliance of the
‘haemochromatosis’ guideline. We expect the most critical
points of misuse and interpretation of iron parameters
and genetic tests, observed in the present study, can be
removed by a more professional evidence-based development
and dissemination of the guideline that is combined by an
appropriate education strategy on its most decisive aspects.
In fact this approach has been adopted by a multidisciplinary
team of medical professionals in the Netherlands, which
recently started to develop an evidence-based guideline
under the auspices of the Medical Scientific Board of the
Dutch Institute for Healthcare CBO, in close cooperation
with the Order of Medical Specialists. These guidelines
will be evidence based and formulated following strict
regulations (www.cbo.nl). Attention will also be paid to
applicability in daily routine and the implementation
strategy. Also, this team may learn from the shortcomings
from the present study. It is expected that implementation
Jacobs, et al. Guideline for HH detection.
J U N E  2 0 0 5 ,  V O L .  6 3 ,  N O .  6
212
of this guideline into medical practice throughout the
Netherlands in around early 2007 will increase compliance
with the guideline, also on the decisive points. 
We summarise that the introduction of a guideline for a
targeted approach to HH screening increased the number
of diagnostic procedures appropriate for HH investigation.
The number of detected HH patients increased non-
significantly, at comparable costs per case detected, with
a drawback of falsely positive HH diagnoses. The HH
overdiagnoses reflected the difficulties in indication and
interpretation of both serum iron parameters and HFE
genotypes. Therefore, the implementation strategy of the
guideline should be improved to increase awareness and
guarantee compliance with the indication and interpretation
of both the iron and genetic parameters.
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